WHO WE ARE

Trimph is an Australian biomedical company that has developed an injectable class of scaffolds that is able to regenerate bone, cartilage and connective tissues. Trimph’s scaffolds are fully synthetic and resorbable to the body. Trimph has a robust Intellectual Property portfolio including a granted patent in the USA and Europe as well as multiple international patent applications.

The technology was co-invented by Dr Ali Fathi during his PhD at the University of Sydney. Ali and Terence founded Trimph in August 2015 and since then, established company’s ISO13485-2016 certified production facility, completed the first in human trial and secured private and public funds. Trimph has manufacturing, regulatory, clinical and technical expertise to launch minimally invasive therapeutic alternatives to improve patient outcomes.

the technology

icon-needle

Injectable

Trimph’s device is an injectable scaffold that can be administered to different injured tissues without the need for invasive surgery.

icon-needle

Temperature Responsive

At body temperature, Trimph’s device forms an adhesive gel to provide a physical scaffold that mimics the matrix formed during the early stages of healing.

icon-needle

Regenerative

Trimph’s physical scaffold compliments the natural healing process by providing an optimised environment for cellular regeneration and repair.

icon-needle

Resorbable

Over time, host cells repair the damaged tissue while Trimph’s scaffold resorbs to the body, leaving healthy tissue.

Production Facility

research-grants

Trimph has established its own cleanroom production facility that is fully equipped to manufacture sterile medical devices. The infrastructure and the associated quality management system are ISO13485:2016 certified. Trimph’s in-house production facility is of a great importance for quality control, protection of technology know-hows, product development and production scalability. In addition, the company’s certified production capability facilitates efficient clinical development.

Clinical Use

Trimph completed its first in human trial in Perth, Australia. The pilot trial involved the use of Trimph’s scaffold for socket preservation post tooth extraction in 10 patients. In all patients, Trimph’s device was successfully administered; there was no need for use of membrane or micro-suturing at the extraction site. This allows the principle investigator (A/Prof Calder) to save time in the theatre. In follow-up visits, wound closure was noted at seven days post-extraction and there was no sign of infection or inflammation in any patients. Three months post use of TrimphDent, tissues biopsies were collected from the site for histochemical analyses; the results showed that the product was fully resorbed and there was no sign pathological abnormality at the site. In addition, active bone remodelling was also noted at the site.

users
100%

Useability

Easily injectable, instant gelation,
and no device malfunctions

100%

Safety

No infection, inflammation
or pain reported

100%

Wound Healing

Wound closure noted
at 7 days post-extraction

90%

Bone Activity

Active bone remodelling
in all collected tissue samples

*Change in treatment plan due to personal circumstances.

Technology

Covalently bonded smart polymer and peptide

In molecular level, Trimph is a water based solution of a propietry patent smart polymer and peptide that are covalently bonded. Upon the injection to the body, the product forms an elastic scaffold (hydrogel). To address different clinical needs, mechanical properties, adhesivity and the resorption rate of Trimph can be tuned.

In molecular level, Trimph is a water based solution of a propietry patent smart polymer and peptide that are covalently bonded. Upon the injection to the body, the product forms an elastic scaffold (hydrogel). To address different clinical needs, mechanical properties, adhesivity and the resorption rate of Trimph can be tuned.

Smart polymer

The smart polymer is poly(N-isopropylacrylamide )-co-(polylactide/2-hydroxy methacrylate)- co -(oligo (ethylene glycol), denoted as PNPHO. Trimph’s smart polymer consists of four main building blocks, called monomers. The chemical composition of PNPHO and the role of each monomer is as follows;

  1. N-isopropylacrylamide to impart temperature curing properties to Trimph
  2. N-acryloxysuccinimide, to be able to bond with peptides to impart the required structural stability to Trimphd
  3. Polylactide/2-hydroxy methacrylate to be able to adjust the mechanical properties of Trimph
  4. Oligo (ethylene glycol) to make PNPHO water soluble.

The smart polymer is poly(N-isopropylacrylamide )-co-(polylactide/2-hydroxy methacrylate)- co -(oligo (ethylene glycol), denoted as PNPHO. Trimph’s smart polymer consists of four main building blocks, called monomers. The chemical composition of PNPHO and the role of each monomer is as follows;

  1. N-isopropylacrylamide to impart temperature curing properties to Trimph
  2. N-acryloxysuccinimide, to be able to bond with peptides to impart the required structural stability to Trimphd
  3. Polylactide/2-hydroxy methacrylate to be able to adjust the mechanical properties of Trimph
  4. Oligo (ethylene glycol) to make PNPHO water soluble.

Peptide

Amine groups of peptides can bond covalently to succinimide ester arms of PNPHO smart polymer. The resorption rate of the final product can be tuned by the degree of crosslinking between PNPHO and peptide. This allows the formulation of Trimph hydrogels with varying physical properties for different clinical applications.

Amine groups of peptides can bond covalently to succinimide ester arms of PNPHO smart polymer. The resorption rate of the final product can be tuned by the degree of crosslinking between PNPHO and peptide. This allows the formulation of Trimph hydrogels with

PLATFORMS

TrimphGlue

TrimphGlue is an injectable elastic scaffold which is easily applied to bone defects. The scaffold is inherently angiogenic and promotes vascular ingrowth. Osteoinductive compounds can be incorporated at low doses, if required.

TrimphGel

TrimphGel is injectable and uses heat from the body to form a regenerative scaffold for soft tissue repair. TrimphGel is fully synthetic and amenable with deep tissue administration.

TrimphDent

TrimphDent is a ready to use injectable scaffold that is applied immediately after tooth extraction to facilitate wound healing in both soft and hard tissue. Unlike other bone substitutes, TrimphDent is delivered to the socket as a liquid to stabilise the blood clot without the need for physical containment.

MILESTONES

Trimph has a robust Intellectual Property portfolio including a granted patent in the USA and Europe as well as multiple international patent applications. The granted patent covers the proprietary smart polymer. Further patent fillings protect specific formulations of the polymer and relevant clinical applications.

Trimph’s production facility in Alexandria, Sydney is capable of producing 500 sterile devices per week. Quality control and quality assurance of the manufacturing process as well as tractability and distribution of products are governed certified quality management.

Trimph has completed cytotoxicity and biocompatibility study in accordance with ISO10993 requirements. Trimph’s devices are well tolerated in the body and biocompatible. In addition, numerous animal studies confirmed the ability of the product for the regeneration of different tissues.

Trimph products are produced locally under the close supervision of Trimph’s technical team at its own production facility. The associated Quality Management System is ISO13485:2016 certified by BSI. The ISO certification covers the production of all Trimph based, sterile and injectable medical devices.

With the aid of NSW Health and Accelerating Commercialisation funding, Trimph completed its First-in-Human Trial. Trimph’s pilot trial was conducted in Perth under ICH/GCP and ISO 14155 requirements. The product was well-tolerated in all patients as there was no report of discomfort, pain, infection or inflammation at the site. Wound closure was also noted within 7 days post tooth extraction. Preliminary results also showed active bone remodelling at the socket site.

The Team

News and Media

07 Jan 2019 | By Bite Magazine

The New Innovators

Since its incorporation in August 2015, Trimph has secured more than $5.2 million in both private and public source. Their sterile facility is located in the Sydney suburb of Alexandria and is a key strategic asset for IP protection, quality control and early access to the Australian market.

Read News
27 Sep 2018 | By Business.gov.au

Trimph – Alleviating the physical and systemic burdens of oral surgeries

In Australia there are almost 300,000 oral and maxillofacial surgeries a year, this is in addition to more than 60,000 hospital visits attributed to post-oral surgery complications. Trimph was founded in August 2015 by Dr Ali Fathi and Terence Abrams with the mission of alleviating the physical and systemic burdens caused by oral and maxillofacial surgeries.

Read News
17 Aug 2017 | By Startup Daily

Biotech startup Trimph has developed a “glue” intended to help regenerate bone tissue

By quickly healing the damaged tissue, Trimph is ultimately intended to reduce the pain and discomfort felt after a tooth has been extracted, an “inherently traumatic procedure”, and reduce the need for a secondary operation used to tend to complications resulting from the initial extraction.

Read News
25 Jul 2017 | By Anthill

This Australian biotech startup has produced a world-first bone “glue” and secured $3.4 million in funding

Australian biotech, Trimph, has successfully completed a first-in-human trial of its proprietary bone “glue”, TrimphDent, the only bone graft substitute in the world to be applied in liquid form, halving the time of patient recovery, and requiring no specialised preparation or additional surgical expertise.

Read News
24 May 2017 | By University of Sydney

Human trials move wonder gel closer to market

The unique gel can be injected into the body to help regenerate damaged tissue such as bones and cartilage. After only five years of development, this patented university-researched biomedical technology will go to human trials.

Read News
18 Jul 2016 | By InnovationAus.com

Trimph: A medtech pioneer startup

An injectable biomaterial that can aid in the regeneration of damaged body tissues such as cartilage, spinal cord and bones will reduce the need for and risks of open surgery. The technology – called Trimph (Temperature-Responsive Modifiable Peptide Hydrogel) – is one of 50 innovations to have snagged a spot in Engineers Australia’s Most Innovative Engineers list.

Read News

CONTACT US

For more information or product for research purposes, please contact us.